Polatuzumab vedotin to treat relapsed or refractory diffuse large B-cell lymphoma, in combination with bendamustine plus rituximab.
Saved in:
| Title: | Polatuzumab vedotin to treat relapsed or refractory diffuse large B-cell lymphoma, in combination with bendamustine plus rituximab. |
|---|---|
| Authors: | Amaya ML; Divisions of Medical Oncology and Hematology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA., Jimeno A; Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA. antonio.jimeno@cuanschutz.edu., Kamdar M; Division of Hematology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA. manali.kamdar@cuanschutz.edu. |
| Source: | Drugs of today (Barcelona, Spain : 1998) [Drugs Today (Barc)] 2020 Apr; Vol. 56 (4), pp. 287-294. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Clarivate Analytics Country of Publication: Spain NLM ID: 101160518 Publication Model: Print Cited Medium: Print ISSN: 1699-3993 (Print) Linking ISSN: 16993993 NLM ISO Abbreviation: Drugs Today (Barc) Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
